ZBH Stock Analysis: Zimmer Biomet Holdings | NYSE
Medical Devices | NYSE, USA | Market Cap: 20.380m USD | 12M Return: 20.6% | US98956P1021 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 209M
EPS Trend: 96.2%
Qual. Beats: 0
Rev. Trend: 98.1%
Qual. Beats: 4
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Zimmer Biomet Holdings, Inc. (ZBH) is a global medical technology company that designs, manufactures, and markets orthopedic reconstructive products, with a core focus on knee and hip implants. Its broader portfolio spans S.E.T. products (sports medicine, biologics, foot and ankle, upper extremities, and trauma) as well as craniomaxillofacial and thoracic products for bone fixation and chest stabilization. The orthopedic medical device sector is characterized by long product lifecycles, high regulatory barriers, and demand tied to an aging global population and rising rates of joint replacement procedures.
The company has increasingly emphasized digital and robotic solutions to complement its implant lines. Its ROSA Robot assists surgeons during total and partial knee arthroplasty, while the ZBEdge Platform integrates robotic and digital technologies to capture and analyze pre-, intra-, and post-operative data. These offerings reflect a broader industry shift toward data-driven, AI-enabled surgical tools designed to improve implant positioning, clinical outcomes, and longitudinal patient monitoring.
Zimmer Biomet serves a wide customer base that includes orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, and healthcare purchasing organizations. The company was founded in 1927, is headquartered in Warsaw, Indiana, and adopted its current name in June 2015 following the combination of Zimmer Holdings and Biomet. As a member of the Healthcare Equipment sub-industry, ZBH operates in a defensive segment where recurring procedure volumes and established surgeon relationships are key competitive advantages.
- Knee and hip implant volumes drive elective procedure recovery
- ROSA Robotics adoption expands against Stryker and J&J competition
- Capital allocation prioritizes debt reduction and dividend growth
| Net Income: 767.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 1.83 > 1.0 |
| NWC/Revenue: 18.98% < 20% (prev 42.84%; Δ -23.86% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.88b > Net Income 767.5m |
| Net Debt (7.10b) to EBITDA (2.29b): 3.11 < 3 |
| Current Ratio: 1.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (191.4m) vs 12m ago -3.72% < -2% |
| Gross Margin: 69.68% > 18% (prev 71.44%; Δ -1.76% > 0.5%) |
| Asset Turnover: 36.45% > 50% (prev 34.11%; Δ 2.34% > 0%) |
| Interest Coverage Ratio: 4.09 > 6 (EBIT TTM 1.18b / Interest Expense TTM 288.5m) |
| A: 0.07 (Total Current Assets 5.13b - Total Current Liabilities 3.50b) / Total Assets 23.5b |
| B: 0.51 (Retained Earnings 12.1b / Total Assets 23.5b) |
| C: 0.05 (EBIT TTM 1.18b / Avg Total Assets 23.5b) |
| D: 1.18 (Book Value of Equity 12.7b / Total Liabilities 10.8b) |
| Altman-Z'' = 3.70 = AA |
| DSRI: 1.06 (Receivables 1.82b/1.60b, Revenue 8.57b/8.01b) |
| GMI: 1.03 (GM 71.44% / 69.68%) |
| AQI: 1.04 (AQ_t 0.68 / AQ_t-1 0.66) |
| SGI: 1.07 (Revenue 8.57b / 8.01b) |
| TATA: -0.05 (NI 767.5m - CFO 1.88b) / TA 23.5b) |
| Beneish M = -2.88 (Cap -4..+1) = A |
As of November 08, 2026, the stock is trading at USD 105.59 with a total of 2,660,306 shares traded. Over the past week, the price has changed by +11.71%, over one month by +17.74%, over three months by +8.93% and over the past year by +20.57%.
Current recommended Stop Loss: 101.20 (which is 4.2% or 1.3 ATR below the current price).
Zimmer Biomet Holdings has received a consensus analysts rating of 3.52. Therefore, it is recommended to hold ZBH.
- StrongBuy: 6
- Buy: 2
- Hold: 19
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 106.9 | 1.2% |
P/E Trailing = 26.9823
P/E Forward = 12.1803
P/S = 2.378
P/B = 1.4665
P/EG = 0.6923
Revenue TTM = 8.57b USD
EBIT TTM = 1.18b USD
EBITDA TTM = 2.29b USD
Long Term Debt = 6.22b USD (from longTermDebt, last quarter)
Short Term Debt = 1.29b USD (from shortTermDebt, last quarter)
Debt = 7.50b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.10b USD (calculated: Debt 7.50b - CCE 399.9m)
Enterprise Value = 27.5b USD (20.4b + Debt 7.50b - CCE 399.9m)
Interest Coverage Ratio = 4.09 (Ebit TTM 1.18b / Interest Expense TTM 288.5m)
EV/FCF = 13.50x (Enterprise Value 27.5b / FCF TTM 2.04b)
FCF Yield = 7.41% (FCF TTM 2.04b / Enterprise Value 27.5b)
FCF Margin = 23.76% (FCF TTM 2.04b / Revenue TTM 8.57b)
Net Margin = 8.96% (Net Income TTM 767.5m / Revenue TTM 8.57b)
Gross Margin = 69.68% ((Revenue TTM 8.57b - Cost of Revenue TTM 2.60b) / Revenue TTM)
Gross Margin QoQ = 71.18% (prev 70.81%)
Tobins Q-Ratio = 1.17 (Enterprise Value 27.5b / Total Assets 23.5b)
Interest Expense / Debt = 3.84% (Interest Expense 288.5m / Debt 7.50b)
Taxrate = 13.09% (115.8m / 884.5m)
NOPAT = 1.02b (EBIT 1.18b * (1 - 13.09%))
Current Ratio = 1.46 (Total Current Assets 5.13b / Total Current Liabilities 3.50b)
Debt / Equity = 0.59 (Debt 7.50b / totalStockholderEquity, last quarter 12.7b)
Debt / EBITDA = 3.11 (Net Debt 7.10b / EBITDA 2.29b)
Debt / FCF = 3.49 (Net Debt 7.10b / FCF TTM 2.04b)
Total Stockholder Equity = 12.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.26% (Net Income 767.5m / Total Assets 23.5b)
RoE = 6.05% (Net Income TTM 767.5m / Total Stockholder Equity 12.7b)
RoCE = 6.24% (EBIT 1.18b / Capital Employed (Equity 12.7b + L.T.Debt 6.22b))
RoIC = 4.90% (NOPAT 1.02b / Invested Capital 20.9b)
WACC = 6.08% (E(20.4b)/V(27.9b) * Re(7.09%) + D(7.50b)/V(27.9b) * Rd(3.84%) * (1-Tc(0.13)))
Discount Rate = 7.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.80 | Cagr: -3.30%
[DCF] Terminal Value 77.97% ; FCFF base≈1.86b ; Y1≈2.13b ; Y5≈3.14b
[DCF] Fair Price = 210.6 (EV 47.3b - Net Debt 7.10b = Equity 40.2b / Shares 190.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 96.15 | EPS CAGR: 4.37% | SUE: 0.13 | # QB: 0
Revenue Correlation: 98.08 | Revenue CAGR: 5.96% | SUE: 1.59 | # QB: 4
EPS current Quarter (2027-03-31): EPS=2.11 | Chg30d=-0.42% | Revisions=+21% | Analysts=15
EPS current Year (2026-12-31): EPS=8.54 | Chg30d=+0.03% | Revisions=+17% | GrowthEPS=+4.1% | GrowthRev=+4.4%
EPS next Year (2027-12-31): EPS=9.05 | Chg30d=-0.15% | Revisions=-29% | GrowthEPS=+6.1% | GrowthRev=+3.5%
[Analyst] Revisions Ratio: +10% (up=10, down=8)